Biotech completed $12M Series A financing

Recently, Alioth Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Alioth") announced the completion of nearly 12 million USD of Series A financing. This round of financing was jointly led by Matrix Partners Venture Capital and Legend Capital, two of leading VCs in China. This round of financing funds will be used for the construction of the Alioth Membrane R&D Center, the manufacture capacity scale-up of filter products for pharmaceutical processes, and the expansion of the expert team.

Founded in Shanghai China in 2021, Alioth focuses on the development and application of pharmaceutical processing products, and is committed to providing pharmaceutical companies with high-quality separation and purification solutions that meet the requirements of domestic and foreign regulations. With reference to GMP, Alioth has built its own production bases in Shanghai and Hangzhou in China, with process development laboratories, validation laboratories, and filtration products R&D centers, and established a R&D team led by membrane technology scientists to better ensure the supply chain security of pharmaceutical companies, help customers optimize drug manufacture process development, and improve the production safety of drugs. Alioth adheres to the corporate values of Collaboration, Integrity, Respect and Responsibility to support the development of Chinese and global pharmaceutical companies. As the name "Alioth" implies, Alioth is committed to becoming a shining star in the global pharmaceutical industry value chain.


Jia Qijun, founder and CEO of Alioth, said, "With the fast development of China's biopharmaceutical industry, the pharma processing market has shown a rapid growth trend, and membrane-based filtration as one of the key downstream processes, its global market size has exceeded 5.7 billion USD in 2021 and nearly 500 million USD in the Chinese market*." Pharma-processing-used membrane technology spans the "New Materials" and "Biomedicine" two major strategic focus areas in the "Made in China 2025" central government strategy, the capabilities to bridge these two areas and realize technology transformation and industrialization is the key to break through the "bottleneck" technology in the pharma processing filtration sector. Since the foundation of Alioth, we have begun to actively establish a team of experts in related fields, with innovation-driven, quality-first concept, aiming to create high-quality membrane filtration products and solutions with independent intellectual property rights, hoping to contribute to the development of China's high-end manufacturing and global pharmaceutical industry.”

Roger Sun, Managing Director of Matrix Partners Ventures, said: "Alioth is one of our strategic investments in life sciences tools sector. The company's management team are all from the top foreign enterprises in the field of pharma processing membrane filtration, and soon after its establishment, it has constructed production bases in Shanghai and Hangzhou, and its products have received positive feedback after product test & validation in lots of pharma companies in China. In the post-pandemic era, we believe that the in-depth expertise in pharma filtration processing and R&D capabilities of core membranes are the key for long-term success in this field, which is the core competitiveness of Alioth team. It is expected that the Alioth team can continue to launch high-quality products and contribute to the supply safety of Chinese and global pharma industry.”

Jianfei Wang, Managing Director of Legend Capital, said: "The rapid development of the Chinese pharmaceutical industry has enhanced the market demand for key filtration consumables in pharma processing, the China-US trade war and the COVID epidemic create long-term uncertainty of supply chain safety for pharma processing products, domestic pharma companies are actively searching for qualified local-brand pharma processing solutions. Alioth management team have over 10 years’ experience in pharma processing industry, they are able to develop high-quality filtration products to address market demand and customer pain points, we are truly impressed by their expertise and strong execution. We at Legend Capital will continue to support the realization of the company's long-term development strategy, and empower their collaboration with Chinese and oversea pharma companies.”

Source: Allied Market Research market research report